JPH10298083A - Composition for treatment of hyperlipemia and food for patient of hyperlipemia - Google Patents

Abstract

PROBLEM TO BE SOLVED: To obtain the subject composition and food free tram side actions and having excellent effect by including cultured fungus, cultured lactobacillus and yeast. SOLUTION: This composition and food contain cultured fungus such as cultured powder of Aspergillus oryzae NK, cultured lactobacillus such as cultured powder of Streptococcus faecalis and yeast. The composition is administered in the form of a solid or liquid preparation for oral administration at a daily rate of 1-10 g/head in 1-3 divided doses. It can be used in various food forms. The cultured product can be produced by culturing the microorganisms according to conventional method. Dry yeast described in Japanese Pharmacopoeia can be used as the yeast. The composition is effective for lowering the neutral fat and total cholesterol and remarkably improving the condition of hyperlipemia.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a composition for treating hyperlipidemia or a food product corresponding to hyperlipidemia, comprising a culture of mold, a culture of lactic acid bacteria and yeast.

[0002]

2. Description of the Related Art Hyperlipidemia is a disease caused by excessive intake of food or lack of exercise. The number of patients has been steadily increasing in recent years, and has become a major social problem as a new civilization disease. . Treatment of this disease is exercise therapy, nutritional guidance, drug treatment, etc., but none of them is satisfactory. In pharmacotherapy, there are drugs for treating hyperlipidemia such as clofibrate and bezafibrate, but the problem of side effects has also been pointed out. As a fermented food, there is a report that a culture in which lactic acid bacteria are propagated in skin milk is effective for hyperlipidemia (J.N.
utr. Sci. Vitaminal. : Oda T .;
Et al., 40, 617-621, 1994). The digestive and intestinal nutritional supplement "Kawakamato (registered trademark)" includes a culture obtained by growing mold on a solid medium, and has been favored by consumers for many years because of its excellent effects and no side effects.

[0003]

SUMMARY OF THE INVENTION An object of the present invention is to provide a composition for treating hyperlipidemia or a food for hyperlipidemia which has no side effects and has excellent effects.

[0004]

Means for Solving the Problems The present inventors have conducted various studies to find a newer pharmacological action for "Kawakami Kato (registered trademark)" which has excellent medicinal properties as a digestive and intestinal intestine. The present invention was found to lower the fat content and total cholesterol and to remarkably improve the hyperlipidemia state, thereby completing the present invention. The present invention is a composition for treating hyperlipidemia or a food for hyperlipidemia, comprising a mold culture, a lactic acid bacteria culture and yeast.

[0005] The mold culture used in the present invention is not particularly limited, and examples thereof include cultures of the genus Aspergillus, Penicillium, and Rhizopus. The culture powder of Aspergillus oryzae is preferred, and particularly Aspergillus oryzae NK Culture powder is preferred. The culture of a lactic acid bacterium is not particularly limited, but preferably a culture powder of Bifidobacterium, Lactobacillus acidophilus, or Streptococcus faecalis, and particularly preferably a culture powder of Streptococcus faecalis.

The above Aspergillus oryzae NK bacteria and Streptococcus faecalis bacteria exist as viable bacteria in the product "Strong Wakamoto (registered trademark)" manufactured and sold by the present applicant and are distributed in Japan and overseas. It is a known fungus. The yeast used in the present invention is not particularly limited, but dried yeast of the Japanese Pharmacopoeia is preferred.

The above mold culture can be produced by a method known per se, and may be liquid culture, but solid culture is preferred. The carbon and nitrogen sources used in these media are
Plant-derived ones are preferred, for example, defatted soybeans, defatted wheat germ, defatted rice germ, bran, rice bran, corn germ and the like.These carbon sources and nitrogen sources may be used alone or in combination. May be used. Medium carbon source,
Water is added at a weight ratio of 50 to 100% to the nitrogen source, and after sterilization, a mold conidia such as Aspergillus, Oryzae, or NK is contacted, and the mixture is allowed to stand at 25 to 35 ° C for 2 to 4 days.

[0008] The above-mentioned lactic acid bacteria culture is also used in the same medium as the above-mentioned mold culture, and after adding water and sterilizing, mixing with lactic acid bacteria such as Streptococcus faecalis, and then 30 to 40 minutes.
C. for 25 to 35 hours. The composition of the present invention is administered as a solid or liquid preparation for oral administration due to its pharmacological action. When administered as an oral administration preparation, the effective dosage is 1 g to 10 g / person / day, and the number of administrations is About three times a day is preferred. Further, the composition containing the mold culture, the lactic acid bacteria culture and the yeast of the present invention can be used in various food forms.

When the mold culture, lactic acid bacteria culture and yeast used in the present invention are used as solid preparations such as powders, pills, capsules and tablets, each is 40 parts by weight based on the total weight of the composition.
~ 60% (W / W), 5-20% (W / W) and 30 ~
It is preferably blended at a ratio of 50% (W / W), and after adding an appropriate amount of an excipient as needed, the mixture is evenly mixed to obtain any of the above solid agents according to a conventional method.

The composition of the present invention contains thiamine nitrate, riboflavin,
It is preferable to add nicotinamide and the like. In addition, calcium carbonate, microcrystalline cellulose and the like can be used as an excipient, but calcium carbonate is preferable. As a method for examining the usefulness of the drug for hyperlipidemia, a dietary hyperlipidemia model induced by a diet supplemented with high sucrose and cholesterol, and a streptozotocin-induced diabetic hyperlipidemia model were used. Although detailed results will be described in the section on pharmacological experiments, administration of the composition of the present invention to rats reduced triglyceride fat in rats with a high sucrose-cholesterol diet and hyperlipidemia. Streptozotocin diabetic hyperlipidemic rats reduced triglyceride and cholesterol levels. This proved that the present culture was useful for treating hyperlipidemia.

[0011]

【Example】

[Test Example] Dietary hyperlipidemia model Six-week-old rats were divided into groups by a random assignment method according to weight stratification, and then fed experimental food freely for 2 weeks. The experimental group was a control group fed with powdered normal feed MF (Oriental Yeast Co., Ltd.), a diet containing milk casein as a protein source, corn starch and sucrose as carbohydrates, and cholesterol at a ratio of 1%. A hyperlipidemia control (HLC) group was added, and four groups were set in which 1.5% and 5% of “Strength Wakamoto (registered trademark)” was crushed instead of reducing the amount of corn starch in the HLC feed. . After two weeks of feeding, the rats were fasted overnight and blood was collected from the descending aorta under ether anesthesia. According to a conventional method, serum was separated, and triglyceride in the serum was measured.

2. Streptozotocin-induced diabetic hyperlipidemia model Seven-week-old rats are divided into groups by random assignment according to body weight layer, and after fasting overnight, one group is solvent (control group)
And the remaining group received 60 mg / kg of streptozotocin intravenously in the tail vein. After breeding on a normal MF diet for one week, the urinary glucose of the streptozotocin-administered rat was examined using a test paper for urinary glucose, and the rat showing a urine glucose value of 500 mg / dl was again randomized by body weight. They were grouped by the assignment method. M for the diabetes control (DC) group
The F feed and the "Strong Wakamo (registered trademark)" group were fed a powder feed mixed with "Strong Wakamo (registered trademark)" in MF at a ratio of 1.5 and 5%, respectively, for 2 weeks. After two weeks of feeding, the rats were fasted overnight and blood was collected from the descending aorta under ether anesthesia. Serum was separated and triglyceride and total cholesterol were measured according to a conventional method.

The results obtained are shown in FIG. 1 and FIG. As shown in the figure, those fed this culture reduced triglycerides in high sucrose / cholesterol disease model,
It reduced triglycerides and total cholesterol in streptozotocin-induced diabetic hyperlipidemia model.

[Formulation Examples] Tablets-Strong Wakamoto (registered trademark) tablets Aspergillus oryzae NK bacterial culture powder 50.0 g Lactic acid bacterial culture powder 10.0 g Yeast (vitamin supplemented) 37.0 g Precipitated calcium carbonate 3.0 g The above Aspergillus. Orize / NK bacterial culture powder 50.0
g, lactic acid bacteria culture powder 10.0 g, yeast (vitamin supplement) 3
After 7.0 g and 3.0 g of precipitated calcium carbonate were mixed and equalized, the mixture was tableted by a conventional method to obtain a tablet of 0.25 g per tablet.

[0015]

EFFECT OF THE INVENTION As shown by the results of pharmacological experiments, the present culture has an action of lowering the neutral fats and total cholesterol in blood, so that it can be used as a therapeutic agent for hyperlipidemia and a food for hyperlipidemia. It proved to be useful.

[Brief description of the drawings]

BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a graph showing a decrease in triglyceride in a high sucrose / high cholesterol-induced hyperlipidemia model by feeding a composition of the present invention.

FIG. 2 is a graph showing a decrease in neutral fat and total cholesterol in a streptozotocin-induced diabetic hyperlipidemia model by feeding a composition of the present invention.

 ──────────────────────────────────────────────────続 き Continuation of the front page (72) Inventor Hidehiko Matsukawa 1-3-5 Nihonbashi Muromachi, Chuo-ku, Tokyo Wakamoto Pharmaceutical Co., Ltd. (72) Inventor Yoshiaki Saito 1-3-5 Nihonbashi Muromachi, Chuo-ku, Tokyo Wakamoto Pharmaceutical Co., Ltd.

Claims (1)

[Claims] 1. A composition for treating hyperlipidemia or a food for hyperlipidemia, comprising a mold culture, a lactic acid bacteria culture and yeast.